# Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

> **NCT05331183** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 297 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ELX/TEZ/IVA
- **DRUG:** IVA

## Key facts

- **NCT ID:** NCT05331183
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-23
- **Primary completion:** 2027-04-06
- **Final completion:** 2027-04-06
- **Target enrollment:** 297 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05331183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05331183, "Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05331183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*